Page 195 - Mployee Wellness Programs News Today

Astellas has become an active player in gene therapy. MedCity News caught up with company executive Richard Wilson, who explained Astellas’s strategy, the clinical holds on its two most advanced programs, and the rationale behind its recent gene therapy deals.

Check out executive hires from SnapNurse, Almaden Genomics, Dr. Evidence, Healthy.io, Wheel, and Sage Bionetworks.

Amazon's RxPass offers more than 50 generic drugs for more than 80 common conditions at the flat fee of $5 a month for Prime members. While one expert says its a significant move by Amazon, another said more needs to be done.

After another insightful conference this year, these are some of the key legal deal trends to expect from the health care and life sciences industries in 2023.

A contentious debate regarding whether or not nurse practitioners should have more freedom and be less tethered to doctors continues as lawmakers in Pennsylvania spark discussion.

MedCity News is pleased to announce a six-member advisory board that will guide the annual INVEST conference, May 22-24 at the Ritz Carlton Hotel in Chicago.

Ransomware group BlackCat has been targeting healthcare organizations in recent months, and it just went after NextGen Healthcare. Healthcare organizations would be wise to enhance their cybersecurity strategy in defense against BlackCat, as it is “one of the more adaptable ransomware operations in the world,” according to HHS.

The FDA approved TheracosBio’s Brenzavvy as a treatment for type 2 diabetes. But before it won a regulatory nod for controlling blood glucose in adults, it was approved at a different dose (with flavor) as a veterinary product.

Medtech companies should have a team of FDA advisors at the ready to develop and implement pre- and post-market strategies, prevent and resolve pre- or post-market issues and guide lifecycle management

Clinical trial setbacks and financial challenges have led Finch Therapeutics to stop a Phase 3 study for its lead microbiome program, a potential treatment for recurrent C. diff infection. As Finch seeks buyers for its remaining assets, the biotech is laying off most of its staff in a corporate restructuring.